Similar articles

• [Nephrogenic systemic fibrosis].

  Cavallini L, Abaterusso C, Bedogna V, Pertica N, Loschiavo C, Lupo A. Cavallini L, et al. G Ital Nefrol. 2008 Jan-Feb;25(1):14-20. G Ital Nefrol. 2008. PMID: 18264914 Review. Italian.
• Gadolinium and kidney disease: are your patients at risk?

  Hollister D. Hollister D. Nephrol Nurs J. 2008 Mar-Apr;35(2):196-7. Nephrol Nurs J. 2008. PMID: 18472687 No abstract available.
• How should nephrologists approach gadolinium-based contrast imaging in patients with kidney disease?

  Perazella MA. Perazella MA. Clin J Am Soc Nephrol. 2008 May;3(3):649-51. doi: 10.2215/CJN.00670208. Epub 2008 Apr 2. Clin J Am Soc Nephrol. 2008. PMID: 18385396 No abstract available.
• Gadolinium-associated nephrogenic systemic fibrosis: the need for nephrologists' awareness.

  Canavese C, Mereu MC, Aime S, Lazzarich E, Fenoglio R, Quaglia M, Stratta P. Canavese C, et al. J Nephrol. 2008 May-Jun;21(3):324-36. J Nephrol. 2008. PMID: 18587720 Review.
• Is there a causal relation between the administration of gadolinium based contrast media and the development of nephrogenic systemic fibrosis (NSF)?

  Thomsen HS, Morcos SK, Dawson P. Thomsen HS, et al. Clin Radiol. 2006 Nov;61(11):905-6. doi: 10.1016/j.crad.2006.09.003. Clin Radiol. 2006. PMID: 17018301 No abstract available.